Blood-based biomarkers have the potential to revolutionize clinical practice and clinical trials in Alzheimer disease (AD). However, to date, this “holy grail” opportunity has not been realized owing to a broad range of issues, including the lack of a clearly defined context of use (COU), lack of standardization of methods, and numerous failures at replication. Recently, however, a shift in the paradigm has occurred, with my colleagues and I proposing specific COUs for blood-based biomarkers along with potential paradigms for advancing from discovery to clinic and potential acceptable standards.1,2
Check our Research Grants!
Do Women with Preeclampsia have Accelerated Brain Aging? Brain Health in Persons of African Ancestry in Tobago. Does the Brain Help You Walk Better as You Age? Do Brain and Body Energetics Influence Fatigue in Older Age? How Exercise Influences the Brain: Virtual...
